Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22983264 | 0.89 | RAB9A (0.60) | MAPTNPSR1GFERRAB9ASMN1; SMN2 | |
| Nicametate SCHEMBL5060940 | 0.86 | L3MBTL1 (0.68) | MAPTNPSR1SMN1; SMN2ALDH1A1GAA | |
| Nicametate SCHEMBL34040 | 0.86 | L3MBTL1 (0.68) | MAPTNPSR1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13683778 | 0.85 | NPSR1 (0.63) | MAPTNPSR1GFERRAB9ASMN1; SMN2 | |
| SCHEMBL7336785 | 0.85 | ALDH1A1 (0.79) | MAPTNPSR1GFERRAB9ASMN1; SMN2 | |
| Nicametate SCHEMBL28346401 | 0.82 | L3MBTL1 (0.63) | MAPTNPSR1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL5582633 | 0.81 | SMN1; SMN2 (0.69) | MAPTNPSR1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL13989069 | 0.81 | SMN1; SMN2 (0.53) | MAPTNPSR1RAB9ASMN1; SMN2NPC1 | |
| Procaine SCHEMBL9312338 | 0.80 | CYP2D6 (0.69) | MAPTNPSR1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL14083866 | 0.79 | TRPV1 (0.61) | MAPTSMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-09-09 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-20070010700-A1 | Safety containers for biologically active substances and method for producing said container | BAXTER INTERNATIONAL INC (US) | 2007-01-11 | — | — | US | disclosed |
| EP-1079832-B1 | USE OF VITAMIN PP COMPOUNDS | KLINGE CO CHEM PHARM FAB (DE) | 2005-11-30 | — | — | EP | disclosed |
| EP-1585679-A1 | SAFETY CONTAINERS FOR BIOLOGICALLY ACTIVE SUBSTANCES AND METHOD FOR PRODUCING SAID CONTAINER | Baxter Healthcare S.A. (CH) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063036-A1 | SAFETY CONTAINERS FOR BIOLOGICALLY ACTIVE SUBSTANCES AND METHOD FOR PRODUCING SAID CONTAINER | BAXTER HEALTHCARE S.A. (CH) | 2004-07-29 | — | — | WO | disclosed |
| EP-1079832-A1 | USE OF VITAMIN PP COMPOUNDS | Klinge Pharma GmbH (DE) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999053920-A1 | USE OF VITAMIN PP COMPOUNDS | KLINGE PHARMA GMBH (DE) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | MAPT 1527/4885NPSR1 434/4885GFER 4220/4885 |
| US-20100227896-A1 | USE OF VITAMIN PP COMPOUNDS | PNPO, NAMPT, NAPRT | MAPT 2497/4885NPSR1 2343/4885GFER 1982/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | MAPT 3341/4885NPSR1 4550/4885GFER 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.